Takeda Global Research & Development Center, Inc. US has named Azmi Nabulsi as president. Nabulsi will report to Nancy Joseph-Ridge, general manager, pharmaceutical development division, Takeda Pharmaceuticals International. In his role as president, Nabulsi will lead Takeda’s US drug development activities, including the identification of new product candidates, execution of clinical trial programs and support for lifecycle management on Takeda’s marketed products. Nabulsi joined Takeda in 2004, and was previously general manager for Takeda’s strategic development department in Osaka, Japan. Prior to Takeda, he worked for 10 years in various development capacities at Abbott.
Pfizer announced the appointment of Freda Lewis-Hall to chief medical officer and senior vice president. In her new position, Lewis-Hall will be responsible for company-wide medical, patient safety and regulatory affairs. She will report to Jeffrey Kindler, Pfizer’s chairman and CEO. Lewis-Hall was most recently at Vertex Pharmaceuticals, where she worked on clinical and non-clinical development, as well as medical and regulatory. Prior to Vertex, Lewis-Hall was SVP, medical affairs at Bristol-Myers Squibb.
Biopharma CytRX Corp. announced the appointment of Jaisim Shah to chief business officer and SVP of business development. Shah previously held senior level positions in development, marketing and commercial operations, most recently at PDL BioPharma, and its spinoff Facet Biotech Corp. He has also served as VP, worldwide franchise management/global marketing and US marketing at Bristol-Myers Squibb. Prior to BMS, Shah was global business leader, oncology/virology at Hoffman La-Roche AG.
